AP771A - Vaccines containing a saponin and a sterol. - Google Patents

Vaccines containing a saponin and a sterol. Download PDF

Info

Publication number
AP771A
AP771A APAP/P/1997/001123A AP9701123A AP771A AP 771 A AP771 A AP 771A AP 9701123 A AP9701123 A AP 9701123A AP 771 A AP771 A AP 771A
Authority
AP
ARIPO
Prior art keywords
antigen
virus
mpl
vaccine
vaccine composition
Prior art date
Application number
APAP/P/1997/001123A
Other languages
English (en)
Other versions
AP9701123A0 (en
Inventor
Nathalie Marie-Josephe Claude Garcon-Johnson
Martin Friede
Original Assignee
Smithkline Beecham Biologicals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306923&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP771(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9508326.7A external-priority patent/GB9508326D0/en
Priority claimed from GBGB9513107.4A external-priority patent/GB9513107D0/en
Application filed by Smithkline Beecham Biologicals S A filed Critical Smithkline Beecham Biologicals S A
Publication of AP9701123A0 publication Critical patent/AP9701123A0/xx
Application granted granted Critical
Publication of AP771A publication Critical patent/AP771A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
APAP/P/1997/001123A 1995-04-25 1996-04-01 Vaccines containing a saponin and a sterol. AP771A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9508326.7A GB9508326D0 (en) 1995-04-25 1995-04-25 Vaccines
GBGB9513107.4A GB9513107D0 (en) 1995-06-28 1995-06-28 Vaccines
PCT/EP1996/001464 WO1996033739A1 (en) 1995-04-25 1996-04-01 Vaccines containing a saponin and a sterol

Publications (2)

Publication Number Publication Date
AP9701123A0 AP9701123A0 (en) 1997-10-31
AP771A true AP771A (en) 1999-10-07

Family

ID=26306923

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001123A AP771A (en) 1995-04-25 1996-04-01 Vaccines containing a saponin and a sterol.

Country Status (36)

Country Link
EP (3) EP0955059B1 (cs)
JP (1) JP3901731B2 (cs)
KR (1) KR100463372B1 (cs)
CN (3) CN1248737C (cs)
AP (1) AP771A (cs)
AR (1) AR001686A1 (cs)
AT (2) ATE373487T1 (cs)
AU (2) AU693022B2 (cs)
BG (1) BG63491B1 (cs)
BR (1) BR9608199B1 (cs)
CA (1) CA2217178C (cs)
CY (1) CY2588B2 (cs)
CZ (1) CZ296216B6 (cs)
DE (2) DE69637254T2 (cs)
DK (2) DK0822831T4 (cs)
DZ (1) DZ2026A1 (cs)
EA (1) EA000839B1 (cs)
ES (2) ES2293708T3 (cs)
GR (1) GR3031912T3 (cs)
HU (1) HU227944B1 (cs)
IL (1) IL118004A (cs)
MA (1) MA23850A1 (cs)
MY (1) MY134811A (cs)
NO (1) NO322190B1 (cs)
NZ (1) NZ305365A (cs)
OA (1) OA10629A (cs)
PL (1) PL184061B1 (cs)
PT (1) PT955059E (cs)
RO (1) RO119068B1 (cs)
SA (1) SA96170297B1 (cs)
SI (2) SI0822831T2 (cs)
SK (1) SK282017B6 (cs)
TR (1) TR199701252T1 (cs)
TW (1) TW515715B (cs)
UA (1) UA56132C2 (cs)
WO (1) WO1996033739A1 (cs)

Families Citing this family (504)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
RU2127605C1 (ru) * 1996-05-22 1999-03-20 Юрий Леонидович Криворутченко Способ стимулирования гуморального и клеточного иммунного ответа на целевой антиген
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
WO1999010008A1 (en) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69815692T2 (de) * 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9724531D0 (en) 1997-11-19 1998-01-21 Smithkline Biolog Novel compounds
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
PT1584685E (pt) 1998-02-05 2011-06-17 Glaxosmithkline Biolog Sa Derivados de antigénios associados a tumores da família mage, utilizados para a preparação de proteínas de fusão com epítopos auxiliares t e de composições para vacinação
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU753995B2 (en) 1998-04-07 2002-10-31 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TR200100373T2 (tr) 1998-08-07 2001-09-21 University Of Washington İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
BRPI9915545B8 (pt) * 1998-10-16 2021-05-25 Glaxosmithkline Biologicals Sa composição de vacina, processo para preparação da mesma e kit compreendendo dois recipientes.
BR9916020A (pt) 1998-12-08 2002-01-22 Corixa Corp Compostos e métodos para o tratamento e diagnóstico de infecção por chlamydia
ATE527360T1 (de) 1998-12-08 2011-10-15 Glaxosmithkline Biolog Sa Neue verbindungen abgeleitet von neisseria meningitidis
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
HK1039895B (en) 1999-02-17 2010-12-03 Csl Limited Immunogenic complexes and methods relating thereto
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
WO2000055327A2 (en) 1999-03-12 2000-09-21 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
DE60038166T2 (de) 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
BR0009505A (pt) 1999-04-02 2002-06-11 Corixa Corp Compostos e processos para terapia e diagnóstico de câncer de pulmão
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU764969B2 (en) * 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
EP1227837B1 (en) 1999-10-22 2008-05-21 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
WO2001041802A1 (en) * 1999-12-08 2001-06-14 Statens Veterinärmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
SI1265915T1 (sl) 2000-02-23 2011-02-28 Glaxosmithkline Biolog Sa Nove spojine
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1385541B1 (en) * 2000-04-13 2008-06-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
EP1278855B1 (en) 2000-04-21 2008-03-12 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
ATE346925T1 (de) 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
CA2413959C (en) 2000-06-20 2015-07-07 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE60134158D1 (de) 2000-06-28 2008-07-03 Corixa Corp Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
US20030180316A1 (en) 2000-06-29 2003-09-25 Dominique Boutriau Multivalent vaccine composition
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
DE60131670T2 (de) * 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
BR0114786A (pt) * 2000-10-18 2003-08-12 Glaxosmithkline Biolog Sa Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
EP1201250A1 (en) * 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
EP1409533A2 (en) * 2001-01-26 2004-04-21 Walter Reed Army Institute of Research Recombinant plasmodium falciparum merozoite protein-1/42 vaccine
US7306806B2 (en) 2001-01-26 2007-12-11 United States Of America As Represented By The Secretary Of The Army Recombinant P. falciparum merozoite protein-142 vaccine
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002067983A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
JP5208347B2 (ja) * 2001-02-23 2013-06-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規なワクチン
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
CA2452382A1 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
EP2248822B1 (en) 2001-07-27 2016-11-23 GlaxoSmithKline Biologicals SA Meningococcus adhesins
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
MXPA04010255A (es) 2002-04-19 2008-03-04 Univ Toronto Metodos inmunologicos y composiciones para el tratamiento de la enfermedad de alzheimier.
ATE494907T1 (de) 2002-07-18 2011-01-15 Univ Washington Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
EP1524993B1 (en) 2002-08-02 2013-03-06 GlaxoSmithKline Biologicals s.a. Neisserial vaccine compositions comprising a combination of antigens
ATE492288T1 (de) 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
EP1569515A4 (en) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa MALARIA vaccine method
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
SI1581812T1 (sl) 2003-01-06 2008-10-31 Wyeth Corp Sestavki in postopki za diagnosticiranje in zdravljenje raka kolona
ES2303046T3 (es) * 2003-01-29 2008-08-01 Pfizer Products Inc. Vacunas caninas contra bordetella bronchiseptica.
US20050089533A1 (en) * 2003-01-29 2005-04-28 Joseph Frantz Canine vaccines against Bordetella bronchiseptica
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
WO2004087204A2 (en) 2003-04-04 2004-10-14 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
WO2005032582A2 (en) 2003-07-31 2005-04-14 Chiron Corporation Immunogenic compositions for streptococcus pyogenes
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
CA2885040C (en) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1667712B1 (en) 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigens and use thereof in vaccination
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
CA2551560A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US8080253B2 (en) 2004-02-05 2011-12-20 The Ohio State University Research Foundation Chimeric VEGF peptides
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
JP5600375B2 (ja) 2004-03-09 2014-10-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド インフルエンザウイルスワクチン
PT1742659E (pt) * 2004-04-05 2013-06-03 Pah Usa 15 Llc Emulsões de óleo em água microfluidizadas e composições de vacinas
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
CA2837748C (en) 2004-05-25 2016-03-08 Oregon Health And Science University Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
ATE491467T1 (de) 2004-05-28 2011-01-15 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
NZ593693A (en) 2004-09-22 2013-08-30 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal proteins
WO2006042156A2 (en) 2004-10-08 2006-04-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS represneted by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Modulation of replicative fitness by using less frequently used synonymous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
CN101072875B (zh) 2004-12-07 2011-05-18 东丽株式会社 新型癌抗原肽及其用途
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
ATE552267T1 (de) 2005-02-18 2012-04-15 Novartis Vaccines & Diagnostic Immungene von uropathogenen escherichia coli
SG160329A1 (en) 2005-02-18 2010-04-29 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
WO2006100111A1 (en) 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US8541007B2 (en) 2005-03-31 2013-09-24 Glaxosmithkline Biologicals S.A. Vaccines against chlamydial infection
EA014527B1 (ru) 2005-03-31 2010-12-30 Глаксосмитклайн Байолоджикалс С.А. Вакцины против хламидиоза
ES2381492T3 (es) 2005-04-29 2012-05-28 Glaxosmithkline Biologicals Sa Procedimiento de prevención o tratamiento de infección por M. tuberculosis
CA2612394C (en) 2005-06-15 2017-02-21 The Ohio State University Research Foundation Her-2 peptides
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1910410B1 (en) 2005-07-01 2011-10-26 Forsyth Dental Infirmary for Children Tuberculosis antigen detection assays and vaccines
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
US20110223197A1 (en) 2005-10-18 2011-09-15 Novartis Vaccines And Diagnostics Inc. Mucosal and Systemic Immunization with Alphavirus Replicon Particles
PL1951296T5 (pl) 2005-11-01 2015-06-30 Seqirus Uk Ltd Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego poprzez traktowanie beta-propiolaktonem
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
PL3017827T3 (pl) 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Szczepionka z koniugatem polisacharydu pneumokokowego
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
WO2007082105A2 (en) 2006-01-16 2007-07-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chlamydia vaccine
ES2809167T3 (es) 2006-01-17 2021-03-03 Forsgren Arne Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE)
JP6087041B2 (ja) 2006-01-27 2017-03-08 ノバルティス アーゲー 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2382987A1 (en) 2006-03-24 2011-11-02 Novartis Vaccines and Diagnostics GmbH Storage of influenza vaccines without refrigeration
MX337528B (es) 2006-03-30 2016-03-09 Glaxosmithkline Biolog Sa Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
CN101460192A (zh) 2006-03-30 2009-06-17 恩布里克斯公司 家禽疫苗接种的方法和组合物
WO2007126825A2 (en) 2006-03-31 2007-11-08 Novartis Ag Combined mucosal and parenteral immunization against hiv
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2390353A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the CD69 gene.
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
EP2032160B2 (en) 2006-06-12 2013-04-03 GlaxoSmithKline Biologicals S.A. Vaccine
CN101479293A (zh) 2006-06-29 2009-07-08 诺华有限公司 脑膜炎奈瑟球菌多肽
PT2043682E (pt) 2006-07-17 2014-07-11 Glaxosmithkline Biolog Sa Vacina da influenza
AU2007276219B2 (en) 2006-07-18 2013-10-03 Glaxosmithkline Biologicals S.A. Vaccines for malaria
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
ES2387582T3 (es) 2006-09-07 2012-09-26 Glaxosmithkline Biologicals S.A. Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio
AU2007297178B2 (en) 2006-09-11 2014-07-24 Novartis Ag Making influenza virus vaccines without using eggs
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101516396B (zh) 2006-09-26 2013-10-09 传染性疾病研究院 包含合成佐剂的疫苗组合物
SI2086582T1 (sl) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega emulzijo olja v vodi kot adjuvans
HRP20130023T1 (hr) 2006-10-12 2013-02-28 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži emulziju ulje u vodi kao adjuvans
CA2669209C (en) * 2006-11-20 2016-01-26 Duecom Ab Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
US20100055166A1 (en) 2007-03-02 2010-03-04 Gerald Hermann Voss Novel method and compositions
CN101687027B (zh) 2007-04-04 2015-01-28 传染性疾病研究院 包含结核分枝杆菌多肽及其融合的免疫原性组合物
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
EP2377952A1 (en) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Methods for diagnosing and treating astrocytomas
MX2009011837A (es) 2007-05-02 2010-04-22 Glaxosmithkline Biolog Sa Vacuna.
WO2008146164A2 (en) 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
GB0711858D0 (en) * 2007-06-19 2007-07-25 Glaxosmithkline Biolog Sa Vaccine
EP2170379B1 (en) 2007-06-26 2017-03-22 GlaxoSmithKline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
DK2185191T3 (da) 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
PL2182983T3 (pl) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
HUE025149T2 (hu) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimer multiepitóp influenza vakcinák
JP2010535504A (ja) 2007-08-03 2010-11-25 プレジデント アンド フェロウズ オブ ハーバード カレッジ クラミジア抗原
NZ583150A (en) 2007-08-13 2012-05-25 Glaxosmithkline Biolog Sa Use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum in the manufacture of a medicament for vaccinating infants against malaria
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
BRPI0816689B1 (pt) 2007-09-12 2021-08-24 Novartis Ag Composição de vacina, kit e método para a confecção de uma composição de vacina para a prevenção ou tratamento de infecção por streptococcus pyogenes
EA017879B1 (ru) 2007-09-17 2013-03-29 Онкометилом Сайенсиз Са Улучшенное определение экспрессии mage-a
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
ES2824684T3 (es) 2007-10-25 2021-05-13 Toray Industries Inductor de la respuesta inmunitaria
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
US8637053B2 (en) 2007-12-03 2014-01-28 President And Fellows Of Harvard College Chlamydia antigens
PT2227483T (pt) 2007-12-19 2017-06-21 Henry M Jackson Found Advancement Military Medicine Inc Formas solúveis da glicoproteína f de vírus hendra e nipah e suas utilizações
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
DK2235046T3 (da) 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
ES2597439T3 (es) 2007-12-24 2017-01-18 Id Biomedical Corporation Of Quebec Antígenos recombinantes del VSR
NZ596805A (en) 2008-02-21 2013-06-28 Novartis Ag Meningococcal fHBP polypeptides
EP2268309B1 (en) 2008-03-18 2015-01-21 Novartis AG Improvements in preparation of influenza virus vaccine antigens
PT2271360E (pt) 2008-04-16 2015-12-07 Glaxosmithkline Biolog Sa Vacina
JP2011518186A (ja) 2008-04-18 2011-06-23 ザ ジェネラル ホスピタル コーポレイション 自己集合性ワクチンを使用する免疫療法
US9314515B2 (en) 2008-04-25 2016-04-19 Ludwig Institute For Cancer Research Ltd. Targeted treatment for patients with estrogen receptor negative and progesterone receptor negative breast cancers
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan NANO EMULSION VACCINES
JP5689796B2 (ja) 2008-08-01 2015-03-25 ガマ ワクチンズ ピーティワイ リミテッド インフルエンザワクチン
MX339277B (es) 2008-08-05 2016-05-19 Toray Industries Agente inductor de inmunidad.
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010036938A2 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
KR20110091560A (ko) 2008-12-03 2011-08-11 프로테아 벡신 테크놀로지스 엘티디. 글루타밀 ｔＲＮＡ 합성효소(ＧｔＳ) 단편들
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
NZ700477A (en) 2009-02-17 2016-04-29 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
KR20110128316A (ko) 2009-02-20 2011-11-29 가니메드 파마슈티칼스 아게 암의 진단 및 치료를 위한 방법 및 조성물
EP2403526B1 (en) 2009-03-06 2019-05-15 GlaxoSmithKline Biologicals SA Chlamydia antigens
AU2010225125A1 (en) 2009-03-17 2011-10-20 Glaxosmithkline Biologicals S.A. Improved detection of gene expression
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
SG176532A1 (en) 2009-06-15 2012-01-30 Univ Singapore Influenza vaccine, composition, and methods of use
CA2765511C (en) 2009-06-16 2015-05-12 The Regents Of The University Of Michigan Nanoemulsion vaccines
PE20121541A1 (es) 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa Antigenos de virus de sincicio respiratorio recombinantes
US8889146B2 (en) 2009-06-24 2014-11-18 Glaxosmithkline Biologicals, Sa Vaccine
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
HRP20220756T1 (hr) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
ES2526996T3 (es) 2009-07-16 2015-01-19 Novartis Ag Inmunógenos desintoxicados de Escherichia coli
CN103977394B (zh) 2009-07-17 2016-03-09 翰林大学校产学协力团 包含脂质体包胶的寡核苷酸和表位的免疫刺激性组合物
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013502456A (ja) 2009-08-26 2013-01-24 アールエヌエー アイエヌシー リポタイコ酸由来の糖脂質及びこれを含む組成物
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
US20120283115A1 (en) 2009-08-31 2012-11-08 Ludwig Institute For Cancer Research Ltd. Seromic analysis of ovarian cancer
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
BR112012005518B1 (pt) 2009-09-10 2021-11-30 Merial, Inc Novas formulações de vacina compreendendo adjuvantes contendo saponina
KR20120081587A (ko) 2009-09-10 2012-07-19 노파르티스 아게 기도 질병에 대한 조합 백신
WO2011034950A1 (en) 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
RU2603267C2 (ru) 2009-09-30 2016-11-27 Новартис Аг Конъюгация капсульных полисахаридов staphylococcus aureus типа 5 и типа 8
WO2011040978A2 (en) 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Immunodominant mhc dr52b restricted ny-eso-1 epitopes, mhc class ii monomers and multimers, and uses thereof
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP5889196B2 (ja) 2009-11-11 2016-03-22 ガニメド ファーマシューティカルズ アーゲー クローディン６（ｃｌｄｎ６）に特異的な抗体
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
ES2707778T3 (es) 2009-12-30 2019-04-05 Glaxosmithkline Biologicals Sa Inmunógenos polisacáridos conjugados con proteínas portadoras de E. coli
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
CN102869377A (zh) 2010-03-10 2013-01-09 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
EP2366709A1 (en) 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
EP2547695B1 (en) 2010-03-16 2018-05-09 Biontech Protein Therapeutics GmbH Tumor vaccination involving a humoral immune response against self-protein cldn18.2
KR20130063493A (ko) 2010-03-26 2013-06-14 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｉｖ 백신
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2556151A1 (en) 2010-04-07 2013-02-13 Novartis AG Method for generating a parvovirus b19 virus-like particle
US9597326B2 (en) 2010-04-13 2017-03-21 Glaxosmithkline Biologicals Sa Benzonapthyridine compositions and uses thereof
CN102933229A (zh) 2010-06-04 2013-02-13 惠氏有限责任公司 疫苗制剂
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
JP2013533745A (ja) 2010-07-06 2013-08-29 ノバルティス アーゲー ノロウイルスに由来する免疫原性組成物および方法
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
RS56339B1 (sr) 2010-09-20 2017-12-29 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t ćelijski receptori i t ćelijski epitopi
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
MA34802B1 (fr) 2010-10-15 2014-01-02 Glaxosmithkline Biolog Sa Nouvel antigène
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
GB201101331D0 (en) 2011-01-26 2011-03-09 Glaxosmithkline Biolog Sa Compositions and uses
WO2012057904A1 (en) 2010-10-27 2012-05-03 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
BR112013011420A2 (pt) 2010-11-08 2016-08-02 Infectious Disease Res Inst vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN106822882A (zh) 2010-12-14 2017-06-13 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012135177A2 (en) 2011-03-29 2012-10-04 Uab Research Foundation Methods and compositions for cytomegalovirus il-10 protein
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
BR112013029169B1 (pt) 2011-05-13 2021-09-28 Novartis Ag Polipeptídeo f pré-fusão do vírus sincicial respiratório (rsv), composição imunogênica e uso da mesma
NZ724296A (en) 2011-05-13 2020-05-29 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US20140072622A1 (en) 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
RU2634862C2 (ru) 2011-05-19 2017-11-07 Торэй Индастриз, Инк. Агент, индуцирующий иммунитет
RU2614386C2 (ru) 2011-05-19 2017-03-27 Торэй Индастриз, Инк. Средство, индуцирующее иммунитет
RS59369B1 (sr) 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizovane vakcine protiv kancera
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
CN111286537A (zh) 2011-05-24 2020-06-16 生物技术Rna制药有限公司 用于癌症的个体化疫苗
US20130156803A1 (en) 2011-06-04 2013-06-20 Rochester General Hospital Research Institute Compositions and methods related to p6
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
EP2736921B1 (en) 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions and methods for assessing functional immunogenicity of parvovirus vaccines
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
AU2012307157B2 (en) 2011-09-16 2017-08-03 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins TcdA and TcdB of Clostridium difficile
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
LT2782598T (lt) 2011-11-23 2020-07-27 In3Bio Ltd. Rekombinantiniai baltymai ir jų terapinis panaudojimas
WO2013079687A1 (en) 2011-11-30 2013-06-06 The Chancellor, Masters And Scholars Of The University Of Oxford Inkt cell modulators and methods of using the same
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
PT2811981T (pt) 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
WO2013134577A2 (en) 2012-03-08 2013-09-12 Detectogen, Inc. Leishmaniasis antigen detection assays and vaccines
EP2833900B1 (en) 2012-04-01 2018-09-19 Technion Research & Development Foundation Limited Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
HUE039215T2 (hu) 2012-05-16 2018-12-28 Immune Design Corp Vakcinák HSV-2-höz
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
JP2015522580A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー 免疫学的組成物およびその使用
GB201213364D0 (en) 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
EP2879701B1 (en) 2012-08-03 2023-11-15 Access to Advanced Health Institute Compositions and methods for treating an active mycobacterium tuberculosis infection
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
WO2014044728A1 (en) 2012-09-18 2014-03-27 Novartis Ag Outer membrane vesicles
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
KR20150073943A (ko) 2012-10-03 2015-07-01 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
DK2912186T3 (da) 2012-10-24 2021-02-22 Platelet Targeted Therapeutics Llc Behandling rettet mod blodplader
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
EP2925355B1 (en) 2012-11-30 2017-11-15 GlaxoSmithKline Biologicals S.A. Pseudomonas antigens and antigen combinations
ES2939307T3 (es) 2012-12-05 2023-04-20 Glaxosmithkline Biologicals Sa Composición inmunogénica
UY34506A (es) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
PT2970398T (pt) 2013-03-13 2024-06-07 The Us Secretary Department Ofhealth And Human Servic Proteínas f de pré-fusão do vsr e sua utilização
EP2968521A2 (en) 2013-03-15 2016-01-20 GlaxoSmithKline Biologicals S.A. Vaccine
JP6873530B2 (ja) 2013-03-15 2021-05-19 イン3バイオ・リミテッドIn3Bio Ltd. 自己組織化合成タンパク質（Ｓｅｌｆ−Ａｓｓｅｍｂｌｉｎｇ Ｓｙｎｔｈｅｔｉｃ Ｐｒｏｔｅｉｎｓ）
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
JP6525984B2 (ja) 2013-06-26 2019-06-05 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル デングウイルスワクチンのための方法および組成物
EP3027203B1 (en) 2013-07-30 2020-07-29 BioNTech SE Tumor antigens for determining cancer therapy
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
WO2015063611A2 (en) 2013-11-01 2015-05-07 University Of Oslo Albumin variants and uses thereof
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
US9993541B2 (en) 2013-11-13 2018-06-12 University Of Oslo Outer membrane vesicles and uses thereof
DK3069138T3 (en) 2013-11-15 2019-04-08 Univ Oslo Hf CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
CA2931112A1 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015077442A2 (en) 2013-11-20 2015-05-28 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
EP4353255A3 (en) 2014-02-20 2024-07-03 Vaxart, Inc. Formulations for small intestinal delivery
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
CA2943190A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Non-toxic adjuvant formulation comprising a monophosphoryl lipid a (mpla)-containing liposome composition and a saponin
EP3639850A1 (en) 2014-03-26 2020-04-22 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JP6664338B2 (ja) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物
CA2952118A1 (en) 2014-06-25 2015-12-30 Glaxosmithkline Biologicals S.A. Clostridium difficile immunogenic composition
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
JP6820830B2 (ja) 2014-07-18 2021-01-27 ユニヴァーシティ オブ ワシントン がんワクチン組成物およびその使用方法
WO2016012385A1 (en) 2014-07-21 2016-01-28 Sanofi Pasteur Vaccine composition comprising ipv and cyclodextrins
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
MY179251A (en) 2014-11-02 2020-11-02 Univ North Carolina Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
WO2016091904A1 (en) 2014-12-10 2016-06-16 Glaxosmithkline Biologicals Sa Method of treatment
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CA2977071A1 (en) 2015-02-20 2016-08-25 Board Of Regents, The University Of Texas System Methods and compositions for attenuated chlamydia as vaccine and vector
AU2015384786B2 (en) 2015-03-03 2020-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
US20180071380A1 (en) 2015-03-20 2018-03-15 The Regents Of The University Of Michigan Immunogenic compositions for use in vaccination against bordetella
AU2016236770B2 (en) 2015-03-26 2022-03-10 Gpn Vaccines Pty Ltd Streptococcal vaccine
MX375989B (es) 2015-05-26 2025-03-07 Ohio State Innovation Foundation Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina.
DK3307239T3 (da) 2015-06-12 2020-11-23 Vaxart Inc Formuleringer til indgivelse af RSV- og norovirusantigener i tyndtarmen
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
SG10201913547YA (en) * 2015-10-19 2020-02-27 Cadila Healthcare Ltd New adjuvant and vaccine composition containing the same
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
KR20180077180A (ko) 2015-11-06 2018-07-06 아쥬반스 테크놀로지스 인코포레이티드 트리테르펜 사포닌 유사체
GB201522132D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Vaccine
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
AU2017229991A1 (en) 2016-03-10 2018-10-04 Aperisys, Inc. Antigen-binding fusion proteins with modified HSP70 domains
KR20180127320A (ko) 2016-03-14 2018-11-28 유니버시티에트 이 오슬로 변경된 FcRn 결합을 갖는 조작된 면역글로불린
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
WO2017167768A1 (en) 2016-03-28 2017-10-05 Glaxosmithkline Biologicals S.A. Novel vaccine composition
BR112018069468A2 (pt) 2016-03-28 2019-07-30 Toray Industries agente indutor da imunidade, métodos para preparar uma célula apresentadora de antígeno, para preparar uma célula t citotóxica e para induzir a imunidade
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
US20200148729A1 (en) 2016-05-21 2020-05-14 Infectious Disease Research Institute Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
WO2018015433A2 (en) 2016-07-20 2018-01-25 Biontech Rna Pharmaceuticals Gmbh Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
EP3504230A1 (en) 2016-08-23 2019-07-03 GlaxoSmithKline Biologicals SA Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CA3036218A1 (en) 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
US11466292B2 (en) 2016-09-29 2022-10-11 Glaxosmithkline Biologicals Sa Compositions and methods of treatment
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
WO2018077385A1 (en) 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3600391A1 (en) 2017-03-31 2020-02-05 GlaxoSmithKline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
KR102595238B1 (ko) 2017-04-19 2023-10-26 인스티튜트 포 리서치 인 바이오메드슨 말라리아원충 종충에 결합하는 신규한 말라리아 백신 및 항체.
CA3061205A1 (en) * 2017-04-25 2018-11-01 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3615061A1 (en) 2017-04-28 2020-03-04 GlaxoSmithKline Biologicals S.A. Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) * 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN107375921B (zh) * 2017-06-12 2019-10-29 商丘美兰生物工程有限公司 一种甘草皂苷脂质体免疫佐剂及其制备方法
CA3066020A1 (en) 2017-06-16 2018-12-20 Glaxosmithkline Biologicals Sa Method of treatment
CN111246878A (zh) 2017-07-18 2020-06-05 因斯瑞拜奥有限公司 合成蛋白及其治疗用途
BR112020001768A2 (pt) 2017-08-14 2020-09-29 Glaxosmithkline Biologicals S.A. método de reforçar uma resposta imune pré-existente contra haemophilus influenzae e moraxella catarrhalis não tipáveis em um indivíduo, e, protocolo de vacinação.
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
US20200276299A1 (en) 2017-09-08 2020-09-03 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US11566050B2 (en) 2017-10-18 2023-01-31 The University Of North Carolina At Chapel Hill Methods and compositions for norovirus vaccines and diagnostics
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
WO2019151759A1 (ko) 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 백신 면역보조제
EP3765477A1 (en) 2018-03-15 2021-01-20 BioNTech RNA Pharmaceuticals GmbH 5'-cap-trinucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
MX2020013553A (es) 2018-06-12 2021-02-26 Glaxosmithkline Biologicals Sa Polinucleotidos y polipeptidos de adenovirus.
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
EP3840770A1 (en) 2018-08-23 2021-06-30 GlaxoSmithKline Biologicals SA Immunogenic proteins and compositions
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
WO2020055503A1 (en) 2018-09-14 2020-03-19 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
EP3880805A4 (en) 2018-11-16 2022-07-27 Versitech Limited Live attenuated influenza b virus compositions methods of making and using thereof
US20220000779A1 (en) 2018-12-06 2022-01-06 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
EP3914708A1 (en) 2019-01-24 2021-12-01 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
BR112021017584A2 (pt) 2019-03-05 2021-11-09 Glaxosmithkline Biologicals Sa Regime e composições de imunização contra hepatite b
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
CN114269792B (zh) 2019-06-25 2025-08-08 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途
MX2022000879A (es) 2019-07-21 2022-05-02 Glaxosmithkline Biologicals Sa Vacuna viral terapeutica.
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
JP2022543281A (ja) 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP4477230A3 (en) 2019-08-06 2025-05-14 The University of North Carolina at Chapel Hill Methods and compositions for stabilized recombinant flavivirus e protein dimers
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
JP2022550884A (ja) 2019-10-02 2022-12-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー スタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）ペプチドおよび使用方法
WO2021097347A1 (en) 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
JP2023514825A (ja) 2020-02-26 2023-04-11 ヴェルシテック リミテッド コロナウイルス感染症に対するｐｄ－１ベースのワクチン
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
EP4188427A1 (en) 2020-08-03 2023-06-07 GlaxoSmithKline Biologicals S.A. Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositios thereof
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
CN113980140B (zh) 2020-10-23 2024-06-25 江苏省疾病预防控制中心(江苏省公共卫生研究院) 融合蛋白及其应用
CN116847830A (zh) 2020-10-28 2023-10-03 赛诺菲巴斯德有限公司 含tlr4激动剂的脂质体、其制备和用途
KR20230117166A (ko) 2020-12-02 2023-08-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 공여자 가닥 보완된 FimH
JP7532672B2 (ja) 2021-01-12 2024-08-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド ＦｉｍＨ変異体、それを含む組成物、及びその使用
EP4032547A1 (en) 2021-01-20 2022-07-27 GlaxoSmithKline Biologicals S.A. Hsv1 fce derived fragements for the treatment of hsv
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4304640A1 (en) 2021-03-12 2024-01-17 Northwestern University Antiviral vaccines using spherical nucleic acids
CN117320745A (zh) 2021-03-30 2023-12-29 维拉瓦克斯股份公司 Sars-cov-2亚单位疫苗
WO2022207793A1 (en) 2021-03-31 2022-10-06 Vib Vzw Vaccine compositions for trypanosomatids
KR20230164108A (ko) 2021-04-01 2023-12-01 얀센 파마슈티칼즈, 인코포레이티드 E. coli O18 생물접합체의 생산
BR112023027401A2 (pt) 2021-06-28 2024-03-12 Glaxosmithkline Biologicals Sa Antígenos do vírus influenza
US20240382584A1 (en) 2021-09-23 2024-11-21 Viravaxx AG Hbv vaccine inducing pres-specific neutralizing antibodies
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023079529A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Re-focusing protein booster immunization compositions and methods of use thereof
US20250082745A1 (en) 2021-12-13 2025-03-13 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
US20250101067A1 (en) 2022-01-28 2025-03-27 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US20250161429A1 (en) 2022-02-14 2025-05-22 University Of Georgia Research Foundation, Inc. Pan-pneumovirus vaccine compositions and methods of use thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
GB202405758D0 (en) 2024-04-24 2024-06-05 King S College London Compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003184A1 (en) * 1988-09-30 1990-04-05 Bror Morein Matrix with immunomodulating activity
EP0415794A1 (en) * 1989-09-01 1991-03-06 Mallinckrodt Veterinary Limited Complexes having adjuvant activity
WO1992006710A1 (en) * 1990-10-23 1992-04-30 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn Volksgezondheid En Cultuur Immunogenic complexes, in particular iscoms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0454735T3 (da) * 1989-01-23 1996-10-07 Auspharm Int Ltd Vaccine sammensætning
JP3755890B2 (ja) * 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
WO1994027636A1 (en) * 1993-05-25 1994-12-08 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
AUPM873294A0 (en) * 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9718901D0 (en) † 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990003184A1 (en) * 1988-09-30 1990-04-05 Bror Morein Matrix with immunomodulating activity
EP0415794A1 (en) * 1989-09-01 1991-03-06 Mallinckrodt Veterinary Limited Complexes having adjuvant activity
WO1992006710A1 (en) * 1990-10-23 1992-04-30 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn Volksgezondheid En Cultuur Immunogenic complexes, in particular iscoms

Also Published As

Publication number Publication date
DE69605296T3 (de) 2007-02-15
SI0822831T1 (en) 2000-02-29
IL118004A (en) 1999-11-30
BR9608199B1 (pt) 2009-05-05
CN1111071C (zh) 2003-06-11
AU699213B2 (en) 1998-11-26
ES2293708T3 (es) 2008-03-16
EA199700272A1 (ru) 1998-04-30
EP0822831B1 (en) 1999-11-24
BR9608199A (pt) 1999-05-18
RO119068B1 (ro) 2004-03-30
JP3901731B2 (ja) 2007-04-04
DZ2026A1 (fr) 2002-07-21
CA2217178A1 (en) 1996-10-31
AP9701123A0 (en) 1997-10-31
CN1515245A (zh) 2004-07-28
HK1025244A1 (en) 2000-11-10
KR100463372B1 (ko) 2005-02-28
EP0955059A3 (en) 2000-07-12
NO974859L (no) 1997-10-21
CN1480214A (zh) 2004-03-10
CY2588B2 (en) 2009-11-04
KR19990008003A (ko) 1999-01-25
PT955059E (pt) 2007-11-27
DE69637254T2 (de) 2008-06-19
DK0822831T3 (da) 2000-05-01
PL322968A1 (en) 1998-03-02
AU5334596A (en) 1996-11-18
BG101995A (en) 1998-11-30
CA2217178C (en) 2009-09-29
HK1009086A1 (en) 1999-05-28
PL184061B1 (pl) 2002-08-30
SI0955059T1 (sl) 2008-02-29
MA23850A1 (fr) 1996-12-31
CN1248737C (zh) 2006-04-05
DK0822831T4 (da) 2006-12-27
BG63491B1 (bg) 2002-03-29
UA56132C2 (uk) 2003-05-15
SI0822831T2 (sl) 2006-12-31
WO1996033739A1 (en) 1996-10-31
TR199701252T1 (xx) 1998-03-21
CN1289065C (zh) 2006-12-13
MX9708226A (es) 1998-06-30
NO322190B1 (no) 2006-08-28
EA000839B1 (ru) 2000-04-24
EP0955059B1 (en) 2007-09-19
EP0822831A1 (en) 1998-02-11
SK144297A3 (en) 1998-05-06
EP0884056A1 (en) 1998-12-16
ES2140076T5 (es) 2007-04-16
DE69605296D1 (de) 1999-12-30
AU693022B2 (en) 1998-06-18
DE69605296T2 (de) 2000-05-18
EP0955059A2 (en) 1999-11-10
SK282017B6 (sk) 2001-10-08
SA96170297B1 (ar) 2005-11-15
HUP9801560A3 (en) 1999-07-28
ES2140076T3 (es) 2000-02-16
AR001686A1 (es) 1997-11-26
HU227944B1 (en) 2012-06-28
TW515715B (en) 2003-01-01
HUP9801560A1 (hu) 1998-10-28
CZ337997A3 (cs) 1998-03-18
GR3031912T3 (en) 2000-02-29
ATE186842T1 (de) 1999-12-15
NO974859D0 (no) 1997-10-21
MY134811A (en) 2007-12-31
ATE373487T1 (de) 2007-10-15
CN1182370A (zh) 1998-05-20
OA10629A (en) 2002-09-16
DE69637254D1 (de) 2007-10-31
JPH11504020A (ja) 1999-04-06
IL118004A0 (en) 1996-08-04
NZ305365A (en) 1999-05-28
AU6987398A (en) 1998-07-23
CZ296216B6 (cs) 2006-02-15
EP0822831B2 (en) 2006-08-23
DK0955059T3 (da) 2007-12-17

Similar Documents

Publication Publication Date Title
AP771A (en) Vaccines containing a saponin and a sterol.
US6846489B1 (en) Vaccines containing a saponin and a sterol
AU714930B2 (en) Vaccines
US20110243971A1 (en) Vaccines
HK1045935A1 (en) Vaccine composition containing 3-O deacylated monophosphoryl ester A
HK1020263A (en) Vaccines containing a saponin and a sterol
HK1009086B (en) Vaccines containing a saponin and a sterol
HK1025244B (en) Vaccines containing a saponin and a sterol
MXPA97008226A (es) Vacunas que contienen una saponina y un esterol
HK1060297A (en) Vaccines containing a saponin and a sterol